The newly granted patent enriches Salipro Biotech's comprehensive intellectual property (IP) portfolio, securing its method for stabilizing challenging drug targets. This advancement is crucial for the discovery and development of next-generation therapeutics aimed at complex targets such as G-protein coupled receptors (GPCRs), ion channels, and transporters.

Jens Frauenfeld, CEO of Salipro Biotech, expressed his enthusiasm for the enhanced protection and recognition of their Salipro® platform technology. "This European patent marks a significant enhancement of our IP rights, adding to our already strong patent base across major markets including the US, EU, China, and Japan," stated Frauenfeld. He further emphasized the patent's role in reinforcing Salipro Biotech's commitment to targeting the previously undruggable sectors of drug discovery.

Peter Jahnmatz, Business Development Director, highlighted the strategic implications of this development for partnership and licensing opportunities. "Strengthening our patent portfolio not only solidifies our technological base but also enhances our attractiveness to potential partners," Jahnmatz commented. He mentioned ongoing efforts to expand collaborations with leading pharmaceutical companies, aiming to tackle a wide range of complex drug targets with next-generation therapeutics.

The grant of this European patent is part of Salipro Biotech's continuous effort since 2016 to protect and leverage its unique platform technology. By securing broader protection, the company aims to address unmet medical needs more effectively and accelerate drug discovery programs targeting challenging, undruggable targets.

Salipro Biotech's achievements represent a significant stride in the biotech industry, promising to impact the development of innovative therapeutics profoundly.